The objective of this competitive continuation is to examine the role of 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) and the 1alpha,25-dihydroxyvitamin D3 receptor (VDR) in bone development. The hypothesis of this proposal is that 1,25(OH)2D3, via its receptor, plays an important role in bone formation by directly influencing the expression of osteoinductive growth factors, and early and late response genes in osteoblasts and osteoblast precursors. The application's Specific Aims are to: 1) examine in vivo, in the vitamin D-deficient and the vitamin D-replete state, the time and pattern of expression of the VDR, osteoinductive growth factors and the vitamin D-dependent proteins in limb, vertebral and calvarial tissues from fetal, neonatal, young and adult rats; and to correlate these patterns with bone development. Morphological and histomorphometric patterns occurring as a result of vitamin D deficiency will be compared with those found in the vitamin D-sufficient state; 2) examine the ontogeny of the VDR, osteoinductive growth factors, and vitamin D-dependent proteins in rat demineralized allogeneic bone matrix implanted into vitamin D-deficient or vitamin D-replete rats. The influence of 1,25(OH)2D3 on the expression of osteoinductive growth factors will be assessed in the implanted matrix following the infusion of 1,25(OH)2D3. The role of the VDR will be assessed by blocking the expression of the receptor in the implanted matrix with anti-sense oligonucleotides; 3) examine the mechanism by which 1,25(OH)2D3 influences the development of osteoblasts and early osteoblast precursor cells. Planned experimentation will examine the effect of 1,25(OH)2D3 on fetal human osteoblast cells with respect to the expression of osteoinductive growth factors, the expression of """"""""early response genes,"""""""" the induction of novel """"""""late response genes"""""""" and the development of a mature osteoblast phenotype. VDR expression will be blocked with antisense oligonucleotides in fetal human osteoblast cells and the functional consequences of receptor deficiency determined. Methods to be used include cell culture, immunohistology, in situ hybridization, subtractive hybridization and differential display PCR techniques. The applicant suggests that these studies will provide an understanding of how 1,25(OH)2D3 and its receptor affect the development of bone. Because peak bone mass is an important variable in determining the risk for osteoporosis in later life, an appreciation of the factors affecting the formation of bone could potentially lead to the development of strategies to increase bone mass. These findings would also be applicable to fracture healing, to post-transplantation bone disease, and renal osteodystrophy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK025409-19
Application #
2733986
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Program Officer
Margolis, Ronald N
Project Start
1979-04-01
Project End
2000-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
19
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Griffin, Matthew D; Dong, Xiangyang; Kumar, Rajiv (2007) Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation. Arch Biochem Biophys 460:218-26
Sommer, Stacy L; Berndt, Theresa J; Frank, Elena et al. (2006) Elevated blood pressure and cardiac hypertrophy after ablation of the gly96/IEX-1 gene. J Appl Physiol 100:707-16
Tebben, Peter J; Kalli, Kimberly R; Cliby, William A et al. (2005) Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc 80:745-51
Dong, Xiangyang; Lutz, Ward; Schroeder, Tania M et al. (2005) Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci U S A 102:16007-12
Berndt, Theresa J; Schiavi, Susan; Kumar, Rajiv (2005) ""Phosphatonins"" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289:F1170-82
Kumar, Rajiv; Lutz, Ward; Frank, Elena et al. (2004) Immediate early gene X-1 interacts with proteins that modulate apoptosis. Biochem Biophys Res Commun 323:1293-8
Schiavi, Susan C; Kumar, Rajiv (2004) The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65:1-14
Griffin, Matthew D; Kumar, Rajiv (2003) Effects of 1alpha,25(OH)2D3 and its analogs on dendritic cell function. J Cell Biochem 88:323-6
Singh, Ravinder J; Kumar, Rajiv (2003) Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc 78:826-9
Griffin, Matthew D; Xing, Nianzeng; Kumar, Rajiv (2003) Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 23:117-45

Showing the most recent 10 out of 96 publications